Biocon Ltd. — Regulatory Filings 2019

May 24, 2019

Biocon Limited

20th KM Hosur Road Electronics City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CJN: l24234KA1978PLC003417

www.biocon.com

May 24,2019

To
The Secretary
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai -400 050
Scrip Symbol- BIOCON

Subject: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 ("SEBI Listing Regulation")

Dear Sir/Madam

In Compliance with Regulation 23(9) of SEBI Listing Regulations, please find enclosed disclosure of related party transactions on consolidated basis for the period ended March 31, 2019, drawn in accordance with applicable accounting standard.

The above information will also be available on the website of the company at www.biocon.com.

Kindly take on record the above information and acknowledge.

Thanking You,

Yours faithfully,

For SIOCON LIMITED

Siddharth Mittal Chief Financial Officer & Compliance Officer Disclosure of related party transactions -On consolidated basis

In pursuance with Regulation 23{9} of SEBI (Listing Obligations and Disclosure Requirements} (Amendments} Regulations, 2018 (All amounts are in Indian Rupees Million}

Name of related parties	Nature of relationship
Key management personnel
Kiran Mazumdar-Shaw	Chairperson & Managing Director
John Shaw	Vice-Chairman & Director
	(w.e.f Jan 12, 1998 and upto July 01, 2017)
Arun Chandavarkar	Joint Managing Director & CEO
Siddharth Mittal	President- Finance and Chief Financial Officer
Satish Kumar 55	Company Secretary
	(w.e.f. Sep 03, 2018 and upto March 15, 2019)
Rajiv Balakrishnan	Company Secretary
	(w.e.f. Jan 24, 2017 and upto March 2, 2018)
Russell Walls	Independent director
Daniel M Bradbury	Independent director
Jeremy M levin	Independent director
Mary Harney	Independent director
Vijay K Kuchroo	Independent director
M Damodaran	Independent director
John Shaw	Non-executive director
	(w.e.f July 1, 2017)
Ravi Mazumdar	Non-executive director
Bobby K Parikh	Independent director
Joint Ventures
NeoBiocon FZ LLC	Joint-venture
Associates
Equillium Inc.	Associate
	(upto October 12, 2018)
Other related parties
Biocon Foundation	Trust in which key management personnel are the Board of Trustees
Mazumdar Shaw Medical Foundation	Trust in which key management personnel are the Board of Trustees
Glentec International limited	Enterprise owned by key management personnel
Catherine Rosenberg	Relative of a director
Jeeves	Enterprise in which relative to a director of the Company Is proprietor
Narayana Hrudayalaya limited	Enterprise in which a director of the Company is a member of board of directors
P K Associates	Proprietary firm of relative of director

The Group has the following related party transactions

Particulars	Transactions/ Balances	March 31, 2019	March 31, 2018
Key management personnel	Salary and perquisites [refer note (a} & (b) below]	90	93
	Sitting fees and commission	36	23
	Sale of Vehicle	1	-
	Sale of equity shares of Blocon Biologics India limited	3	-
	Outstanding as at the year end:
	-Trade and other payables	5	6
Joint Venture	Sale of goods	5	13
	Purchase of goods	1,472	1,632
	Sales promotion expenses	92	82
	Dividend received	216	-
	Expenses incurred on behalf of the related party	1	1
	Outstanding as at the year end:
	-Trade and other receivables	2	13
	-Trade and other payables	1,048	790
Associates	Investment in equity shares	-	3
Other related parties	Sale of goods	83	73
	Sale of services	1	-
	Sale of equity shares of Biocon Biologics India limited	-	-
	Health services availed	8	-
	Expenses towards Scientific and Research services	2	-
	CSR Expenditure	104	100
	Other expenses	36	32
	Outstanding as at the year end:
	-Trade and other receivables	4	15
	-Trade and other payables	-	1

• Amounts are not represented since the amounts are rounded off to Rupees million.

(a) The remuneration to key managerial personnel does not include the provisions made for gratuity and compensated absences, as they are obtained on an actuarial basis for the Company as a whole.

(b) Share-based compensation expense allocable to key management personnel is Rs 8 (March 31, 2018 - Rs 22) which is not Included In the remuneratio_11_ disclosed above.

(c) The above disclosures include related parties as per lnd AS 24 on "Related Party Disclosures" and Companies Act, 2013.

(d) All transl!ctions with these related parties are priced on an arms length basis and none of the balances are secured.